» Articles » PMID: 22012978

Mice Orally Immunized with a Transgenic Plant Expressing the Glycoprotein of Crimean-Congo Hemorrhagic Fever Virus

Overview
Date 2011 Oct 21
PMID 22012978
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

While Crimean-Congo hemorrhagic fever (CCHF) has a high mortality rate in humans, the associated virus (CCHFV) does not induce clinical symptoms in animals, but animals play an important role in disease transmission to humans. Our aim in this study was to examine the immunogenicity of the CCHFV glycoprotein when expressed in the root and leaf of transgenic plants via hairy roots and stable transformation of tobacco plants, respectively. After confirmatory analyses of transgenic plant lines and quantification of the expressed glycoprotein, mice were either fed with the transgenic leaves or roots, fed the transgenic plant material and injected subcutaneously with the plant-made CCHFV glycoprotein (fed/boosted), vaccinated with an attenuated CCHF vaccine (positive control), or received no treatment (negative control). All immunized groups had a consistent rise in anti-glycoprotein IgG and IgA antibodies in their serum and feces, respectively. The mice in the fed/boosted group showed a significant rise in specific IgG antibodies after a single boost. Our results imply that oral immunization of animals with edible materials from transgenic plants is feasible, and further assessments are under way. In addition, while the study of CCHF is challenging, our protocol should be further used to study CCHFV infection in the knockout mouse model and virus neutralization assays in biosafety level 4 laboratories.

Citing Articles

Crimean-Congo haemorrhagic fever (CCHF): present and future therapeutic armamentarium.

Di Bella S, Babich S, Luzzati R, Cavasio R, Massa B, Braccialarghe N Infez Med. 2024; 32(4):421-433.

PMID: 39660152 PMC: 11627488. DOI: 10.53854/liim-3204-2.


Cellular immunity to nucleoproteins (NP) of Crimean-Congo hemorrhagic fever virus (CCHFV) and Hazara Virus (HAZV).

Kalkan-Yazici M, Karaaslan E, Guler-Cetin N, Doymaz M Med Microbiol Immunol. 2024; 213(1):20.

PMID: 39320473 DOI: 10.1007/s00430-024-00802-2.


Crimean-Congo Hemorrhagic Fever Virus for Clinicians-Diagnosis, Clinical Management, and Therapeutics.

Frank M, Weaver G, Raabe V Emerg Infect Dis. 2024; 30(5):864-873.

PMID: 38666553 PMC: 11060459. DOI: 10.3201/eid3005.231648.


CCHFV vaccine development, current challenges, limitations, and future directions.

Ahata B, Akcapinar G Front Immunol. 2023; 14:1238882.

PMID: 37753088 PMC: 10518622. DOI: 10.3389/fimmu.2023.1238882.


Crimean-Congo Hemorrhagic Fever Virus: Progress in Vaccine Development.

Ozdarendeli A Diagnostics (Basel). 2023; 13(16).

PMID: 37627967 PMC: 10453274. DOI: 10.3390/diagnostics13162708.


References
1.
Alvarez M, Pinyerd H, Crisantes J, Rigano M, Pinkhasov J, Walmsley A . Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine. 2006; 24(14):2477-90. DOI: 10.1016/j.vaccine.2005.12.057. View

2.
Papa A, Papadimitriou E, Christova I . The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis. 2010; 43(3):225-9. DOI: 10.3109/00365548.2010.540036. View

3.
Roy S, Tyagi A, Tiwari S, Singh A, Sawant S, Singh P . Rabies glycoprotein fused with B subunit of cholera toxin expressed in tobacco plants folds into biologically active pentameric protein. Protein Expr Purif. 2009; 70(2):184-90. DOI: 10.1016/j.pep.2009.10.002. View

4.
Geisbert T, Bausch D, Feldmann H . Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol. 2010; 20(6):344-57. PMC: 3394174. DOI: 10.1002/rmv.661. View

5.
Di Maro A, Terracciano I, Sticco L, Fiandra L, Ruocco M, Corrado G . Purification and characterization of a viral chitinase active against plant pathogens and herbivores from transgenic tobacco. J Biotechnol. 2010; 147(1):1-6. DOI: 10.1016/j.jbiotec.2010.03.005. View